CVKD vs BMRN vs IQV vs CRL

For growth investors, BioMarin Pharmaceutical Inc.

(BMRN) is the stronger pick with 12. 9% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate BioMarin Pharmaceutical Inc. (BMRN) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, IQVIA Holdings Inc.

(IQV) is the cheapest at 22. 8x versus BioMarin Pharmaceutical Inc. at 30. 1x. On forward P/E, BioMarin Pharmaceutical Inc. is actually cheaper at 13. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, IQVIA Holdings Inc.

(IQV) delivered a total return of -23. 8%, compared to -90. 3% for Cadrenal Therapeutics, Inc. Common Stock (CVKD). Over 10 years, the gap is even starker: IQV returned +166. 6% versus CVKD's -90. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioMarin Pharmaceutical Inc.

(BMRN) is the lower-risk stock at 0. 64β versus Cadrenal Therapeutics, Inc. Common Stock's 2. 07β — meaning CVKD is approximately 226% more volatile than BMRN relative to the S&P 500. On balance sheet safety, BioMarin Pharmaceutical Inc. (BMRN) carries a lower debt/equity ratio of 11% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BioMarin Pharmaceutical Inc.

(BMRN) is pulling ahead at 12. 9% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Cadrenal Therapeutics, Inc. Common Stock grew EPS 23. 9% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, BMRN leads at 15. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BioMarin Pharmaceutical Inc.

(BMRN) is the more profitable company, earning 10. 8% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 10. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMRN leads at 16. 6% versus 0. 0% for CVKD. At the gross margin level — before operating expenses — BMRN leads at 77. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, BioMarin Pharmaceutical Inc.

(BMRN) trades at 13. 6x forward P/E versus 16. 0x for Charles River Laboratories International, Inc. — 2. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BMRN: 69. 1% to $91. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BioMarin Pharmaceutical Inc.

(BMRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 64)). Cadrenal Therapeutics, Inc. Common Stock (CVKD) carries a higher beta of 2. 07 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BMRN: -35. 6%, CVKD: -90. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.